Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
Leukemia Research Reports(2017)
摘要
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation.
更多查看译文
关键词
Chronic lymphocytic leukemia,B-cell receptor inhibitors,Allogeneic hematopoietic stem cell transplantation,TP53 mutation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要